0000899243-20-024407.txt : 20200904
0000899243-20-024407.hdr.sgml : 20200904
20200904210136
ACCESSION NUMBER: 0000899243-20-024407
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200902
FILED AS OF DATE: 20200904
DATE AS OF CHANGE: 20200904
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brunecz Sharon
CENTRAL INDEX KEY: 0001743787
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24260
FILM NUMBER: 201162796
MAIL ADDRESS:
STREET 1: 3854 AMERICAN WAY, SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMEDISYS INC
CENTRAL INDEX KEY: 0000896262
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082]
IRS NUMBER: 113131700
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
BUSINESS PHONE: 2252922031
MAIL ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
FORMER COMPANY:
FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP
DATE OF NAME CHANGE: 19940819
FORMER COMPANY:
FORMER CONFORMED NAME: M&N CAPITAL CORP
DATE OF NAME CHANGE: 19930125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-02
0
0000896262
AMEDISYS INC
AMED
0001743787
Brunecz Sharon
3854 AMERICAN WAY, SUITE A
BATON ROUGE
LA
70816
0
1
0
0
Chief Human Resources Officer
Common Stock
2020-09-02
4
M
0
4367
93.76
A
22100
D
Common Stock
2020-09-02
4
S
0
635
242.01
D
21465
D
Common Stock
2020-09-02
4
S
0
1282
243.53
D
20183
D
Common Stock
2020-09-02
4
S
0
103
244.88
D
20080
D
Common Stock
2020-09-02
4
S
0
724
246.17
D
19356
D
Common Stock
2020-09-02
4
S
0
1538
247.78
D
17818
D
Common Stock
2020-09-02
4
S
0
85
248.37
D
17733
D
Common Stock
117
I
Through 401(k) Plan
Stock Option (right to buy)
93.76
2020-09-02
4
M
0
4367
0.00
D
2028-07-27
Common Stock
4367
8734
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.65 to $242.45, inclusive. The reporting person undertakes to provide to
Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price
within the ranges set forth in footnote (2) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.04 to $244.01, inclusive. The reporting person undertakes to provide to
the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set
forth in footnote (3) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.88 to $245.03, inclusive. The reporting person undertakes to provide to
the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set
forth in footnote (4) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.05 to $246.58, inclusive. The reporting person undertakes to provide to
the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set
forth in footnote (5) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.34 to $248.24, inclusive. The reporting person undertakes to provide to
the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set
forth in footnote (6) to this Form 4.
The information in this report is based on a plan statement dated as of June 30, 2020.
On July 27, 2018, the reporting person was granted an option to purchase 17,468 shares of common stock, subject to time-based vesting. 4,367 of the options vested on each of July 27, 2019 and July 27, 2020,
and the remaining 8,734 options vest ratably on each of July 27, 2021 and July 27, 2022, provided that the reporting person remains continuously employed by the Issuer on each such date, subject to pro-rated
vesting provisions as provided in the award agreement for the stock options.
/s/ Jennifer R. Guckert, pursuant to a power of attorney
2020-09-04